Post by UMCG research

The drug finerenone significantly slows the decline in kidney function in patients with chronic kidney disease (CKD) who do not have diabetes. This is shown by an international study led by clinical pharmacologist hiddo lambers heerspink of the UMCG. This suggests that, for the first time, the drug is also effective in a large group of kidney patients who previously had fewer treatment options. The study results were published today in the NEJM Group The study also shows that finerenone was found to reduce the risk of serious kidney problems, hospitalization for heart failure, or death from cardiovascular disease.  Curious to find out more? https://lnkd.in/esDq_iuF #cdk, #diabetes, #finerenone